RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SinoMab BioScience Stock

SinoMab BioScience Equity 2024

SinoMab BioScience Equity

295.58 M CNY

Ticker

3681.HK

ISIN

HK0000544194

In 2024, SinoMab BioScience's equity was 295.58 M CNY, a -41.99% increase from the 509.58 M CNY equity in the previous year.

SinoMab BioScience Aktienanalyse

What does SinoMab BioScience do?

SinoMab BioScience Ltd is a Chinese biotechnology company specializing in the research, development, and commercial production of innovative biopharmaceutical products. The company was founded in 2001 and is based in Hong Kong. The company's business model focuses on the development of antibody-based therapies for the treatment of cancer and inflammatory diseases. SinoMab BioScience Ltd collaborates closely with leading biopharmaceutical companies, academic institutions, and research facilities worldwide to develop therapeutics that have the potential to improve patients' lives. The company operates in various sectors, including research and development, production, and distribution of biopharmaceutical products. SinoMab also has its own research and development department dedicated to the discovery and development of antibodies. The company aims to build a pipeline of innovative products that address a wide range of medical needs. Currently, SinoMab BioScience Ltd has a range of product candidates in clinical development targeting the treatment of cancer and inflammatory diseases. One of the key products is the antibody preparation SMM-114, used for the treatment of patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma and represents one of the most common cancers in adults. SMM-114 actively inhibits the proliferation of tumor cells by blocking the protein CXCR4, which is expressed on the surface of cancer cells. Another important product candidate of the company is SMAB022, a monoclonal antibody for the treatment of patients with cutaneous squamous cell carcinoma. This product binds to the Epidermal Growth Factor Receptor (EGFR) protein on the surface of cancer cells and inhibits their proliferation. SinoMab BioScience Ltd also has a manufacturing and distribution department for biopharmaceutical products. The company has a GMP-compliant production facility and offers services such as process development, production and purification procedures, stabilization, and formulation of biopharmaceuticals. In addition, SinoMab BioScience Ltd has developed its own in vitro diagnostic (IVD) test for the detection of human papillomavirus (HPV). This disease is one of the most common sexually transmitted infections and is a serious health problem. The HPV IVD is an innovative test system that enables rapid, accurate, and reliable identification of HPV infections. Research and development is highly valued by the company, and it has established its own R&D department consisting of experienced scientists and engineers. This department focuses on the discovery and development of novel biopharmaceutical products and collaborates closely with academic institutions and research facilities. Furthermore, SinoMab BioScience Ltd has formed partnerships with other leading biopharmaceutical companies to collaborate in exploring and harnessing the potential of antibodies for the treatment of diseases. In conclusion, SinoMab BioScience Ltd is an innovative biotechnology company specializing in the development of novel biopharmaceutical therapies for the treatment of cancer and inflammatory diseases. The company has a strong research and development expertise and has built a pipeline of product candidates with the potential to improve patients' lives. With its wide range of products and services in the manufacturing and distribution of biopharmaceuticals, SinoMab BioScience Ltd has established a strong position in the market. SinoMab BioScience ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing SinoMab BioScience's Equity

SinoMab BioScience's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SinoMab BioScience's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating SinoMab BioScience's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

SinoMab BioScience's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in SinoMab BioScience’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about SinoMab BioScience stock

What is the equity of SinoMab BioScience this year?

SinoMab BioScience has equity of 295.58 M CNY this year.

What was the equity of SinoMab BioScience compared to the previous year?

The equity of SinoMab BioScience has increased/decreased by -41.99% decreased compared to the previous year.

What impact does a high equity have on investors of SinoMab BioScience?

A high equity is advantageous for investors of SinoMab BioScience as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of SinoMab BioScience?

A low equity can be a risk for investors of SinoMab BioScience, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of SinoMab BioScience affect the company?

An increase in equity of SinoMab BioScience can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of SinoMab BioScience affect the company?

A reduction in equity of SinoMab BioScience can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of SinoMab BioScience?

Some factors that can affect the equity of SinoMab BioScience include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of SinoMab BioScience so important for investors?

The equity of SinoMab BioScience is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can SinoMab BioScience take to change the equity?

To change equity, SinoMab BioScience can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does SinoMab BioScience pay?

Over the past 12 months, SinoMab BioScience paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SinoMab BioScience is expected to pay a dividend of 0 CNY.

What is the dividend yield of SinoMab BioScience?

The current dividend yield of SinoMab BioScience is .

When does SinoMab BioScience pay dividends?

SinoMab BioScience pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SinoMab BioScience?

SinoMab BioScience paid dividends every year for the past 0 years.

What is the dividend of SinoMab BioScience?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is SinoMab BioScience located?

SinoMab BioScience is assigned to the 'Health' sector.

Wann musste ich die Aktien von SinoMab BioScience kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SinoMab BioScience from 7/11/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 7/11/2024.

When did SinoMab BioScience pay the last dividend?

The last dividend was paid out on 7/11/2024.

What was the dividend of SinoMab BioScience in the year 2023?

In the year 2023, SinoMab BioScience distributed 0 CNY as dividends.

In which currency does SinoMab BioScience pay out the dividend?

The dividends of SinoMab BioScience are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SinoMab BioScience

Our stock analysis for SinoMab BioScience Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SinoMab BioScience Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.